Chandigarh, November 5, 2024 – Venus Remedies Limited, a top exporter of generic drugs to over 80 countries, has reached a major regulatory milestone. The company has received Good Manufacturing Practices (GMP) approval, alongside Pharmaceutical Inspection Co-operation Scheme (PIC/S) accreditation, from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for its advanced pre-filled syringe (PFS) facility in Baddi.
This is the first PIC/S GMP certification for Venus Remedies’ PFS facility. It adds to the company’s existing GMP accreditations from over 25 global regulatory authorities, including the World Health Organization, the European Union, and Saudi Arabia.
Opening Global Doors
The NPRA’s PIC/S certification paves the way for quicker approvals from other PIC/S member nations. This achievement is expected to enhance Venus Remedies’ reach in new markets and meet the growing demand for enoxaparin, a popular anticoagulant used for treating blood clots.
With an annual production capacity of over 20 million enoxaparin units, Venus Remedies is well-positioned for global growth. The worldwide enoxaparin market, valued at $3,315 million in 2023, is projected to grow to $5,415 million by 2030, with a compound annual growth rate (CAGR) of 7.1%.
Also read | NBCC Boosts Healthcare in India with Rs 1,322.48 Crore Projects
Commitment to Quality
Saransh Chaudhary, President of Global Critical Care and CEO of Venus Medicine Research Centre, emphasized the company’s dedication to high-quality pharmaceutical production: “The PIC/S GMP accreditation from Malaysia’s NPRA is a testament to our commitment to quality and technological innovation. This recognition highlights our team’s excellence and our facility’s world-class standards.”
The approval followed a stringent six-month audit, underscoring Venus Remedies’ robust compliance with international manufacturing standards.
Growing International Presence
Aditi Chaudhary, President of International Business at Venus Remedies, celebrated the certification as a milestone in the company’s global expansion efforts. “This accreditation reflects the dedication of our teams. We are ready to extend our footprint and bring high-quality medicines to more markets, ensuring better healthcare access globally.”
With this accreditation, Venus Remedies solidifies its presence in the ASEAN region and strengthens its international stature in the pharmaceutical industry.
